Acute Leukemia Treatment Guidelines

Introduction to Acute Leukemia Treatment

The standard treatment for acute leukemia consists of induction chemotherapy with an anthracycline and cytarabine, followed by consolidation therapy, with treatment approaches varying based on leukemia subtype and patient risk factors, as recommended by the National Comprehensive Cancer Network 1, 2, 3

Acute leukemia is classified into two main types: Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL), each requiring different treatment approaches, according to the National Comprehensive Cancer Network and Annals of Oncology 1, 4
Risk assessment includes patient's age, initial leukocyte count, leukemia subtype, karyotype data, and medical history, as outlined by Annals of Oncology 4, 5
Favorable prognostic factors in AML include chromosomal translocations t(15;17) (acute promyelocytic leukemia), t(8;21), and inv(16), as identified by Annals of Oncology 4
Poor prognostic factors include advanced age (>60 years), antecedent myelodysplastic syndrome, and complex aberrant karyotypes, as reported by Annals of Oncology 4, 5

Induction therapy aims to reduce tumor burden by clearing leukemic cells from bone marrow, as stated by the National Comprehensive Cancer Network 1
For AML in adults under 65 years, the standard regimen includes an anthracycline (e.g., daunorubicin) and cytarabine, according to Annals of Oncology 2, 3
For ALL, induction typically includes vincristine, anthracyclines, corticosteroids, with or without L-asparaginase and/or cyclophosphamide, as recommended by the National Comprehensive Cancer Network 1
For Acute Promyelocytic Leukemia (APL), induction should include an anthracycline and all-trans retinoic acid (ATRA), as outlined by Annals of Oncology 2, 3, 4

Patients achieving complete remission should receive one to two cycles of post-remission therapy, according to Annals of Oncology 2, 3, 4
Good risk patients should receive chemotherapy only, preferably including high-dose cytarabine, as recommended by Annals of Oncology 2, 4
Patients with HLA-identical siblings are candidates for allogeneic stem cell transplantation in first remission, as reported by Annals of Oncology 2, 3
For APL, consolidation should include ATRA, as outlined by Annals of Oncology 4

Maintenance chemotherapy and ATRA are beneficial in APL, according to Annals of Oncology 2, 4

All treatment regimens for ALL include CNS prophylaxis and/or treatment, as recommended by the National Comprehensive Cancer Network 1
Antimetabolites such as methotrexate, cytarabine, and/or mercaptopurine are often included during induction therapy for CNS prophylaxis, as stated by the National Comprehensive Cancer Network 1

Patients in second or subsequent remission may qualify for allogeneic transplantation with an unrelated donor, as reported by Annals of Oncology 2, 4
In relapsed APL, arsenic trioxide can induce remission even if patients have become refractory to ATRA, according to Annals of Oncology 6

Response to induction is monitored through clinical examination, serial peripheral blood counts, and bone marrow aspirates, as outlined by Annals of Oncology 2, 4
Complete remission requires normal cellularity of bone marrow, morphologically normal hematopoiesis, and blast levels <5%, as defined by Annals of Oncology 2, 4

Infectious complications are common and may require prophylaxis, especially with combination therapies, as reported by Leukemia 7
Treatment should be conducted in centers with multidisciplinary expertise and adequate infrastructure, as recommended by Annals of Oncology 2, 4